We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+6.88%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$142M
AUM Growth
-$26.6M
Cap. Flow
-$33.6M
Cap. Flow %
-23.69%
Top 10 Hldgs %
45.91%
Holding
93
New
28
Increased
12
Reduced
11
Closed
39

Top Buys

1
AGN
Allergan plc
AGN
+$6.21M
2
MDVN
MEDIVATION, INC.
MDVN
+$5.39M
3
COO icon
Cooper Companies
COO
+$5.28M
4
BSX icon
Boston Scientific
BSX
+$5.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.11M

Top Sells

1
PRTA icon
Prothena Corp
PRTA
+$4.21M
2
BMY icon
Bristol-Myers Squibb
BMY
+$4.16M
3
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$3.31M
4
ARWR icon
Arrowhead Research
ARWR
+$3.04M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$2.71M

Sector Composition

1 Healthcare 59.79%
2 Technology 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYAX
51
DELISTED
DYAX CORPORATION
DYAX
$624K 0.44%
65,000
-135,000
-68% -$1.03M
ASMB icon
52
Assembly Biosciences
ASMB
$531M
$262K 0.18%
+3,333
New +$236K
PBYI icon
53
Puma Biotechnology
PBYI
$434M
$66K 0.05%
1,000
-10,330
-91% -$735K
ALGN icon
54
Align Technology
ALGN
$12.7B
– –
-35,000
Closed -$1.81M
AMRN
55
Amarin Corp
AMRN
$292M
– –
-15,000
Closed -$543K
ARWR icon
56
Arrowhead Research
ARWR
$10.5B
– –
-185,000
Closed -$3.04M
BIIB icon
57
Biogen
BIIB
$30.4B
– –
-6,471
Closed -$1.98M
BMY icon
58
CALL
Bristol-Myers Squibb
BMY
$124B
– –
-100,000
Closed -$5.2M
BMY icon
59
Bristol-Myers Squibb
BMY
$124B
– –
-80,000
Closed -$4.16M
DRRX
60
DELISTED
DURECT Corp
DRRX
– –
-25,000
Closed -$333K
DVAX
61
DELISTED
Dynavax Technologies
DVAX
– –
-24,734
Closed -$447K
GILD icon
62
CALL
Gilead Sciences
GILD
$167B
– –
-100,000
Closed -$7.09M
ILMN icon
63
Illumina
ILMN
$28.2B
– –
-10,280
Closed -$1.49M
INSM icon
64
CALL
Insmed
INSM
$23.5B
– –
-200,000
Closed -$3.81M
ISRG icon
65
Intuitive Surgical
ISRG
$122B
– –
-45,000
Closed -$2.19M
MMSI icon
66
Merit Medical Systems
MMSI
$4.41B
– –
-175,000
Closed -$2.5M
MRK icon
67
CALL
Merck
MRK
$315B
– –
-262,000
Closed -$14.2M
NVAX icon
68
Novavax
NVAX
$1.35B
– –
-5,000
Closed -$453K
OEF icon
69
PUT
iShares S&P 100 ETF
OEF
$20.1B
– –
-150,000
Closed -$17.5M
PRTA icon
70
Prothena Corp
PRTA
$453M
– –
-110,000
Closed -$4.21M
SGMO
71
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-86,606
Closed -$1.57M
TEVA icon
72
CALL
Teva Pharmaceuticals
TEVA
$37.3B
– –
-150,000
Closed -$7.93M
TNDM icon
73
Tandem Diabetes Care
TNDM
$1.17B
– –
-11,500
Closed -$2.54M
VRTX icon
74
CALL
Vertex Pharmaceuticals
VRTX
$123B
– –
-65,000
Closed -$4.6M
NUVA
75
DELISTED
NuVasive, Inc.
NUVA
– –
-30,000
Closed -$1.15M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Ghost Tree Capital held 93 positions worth $142M, down 16% from $168M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ghost Tree Capital withdrew a net $33.6M in Q2 2014, closing 39 positions and reducing 11 holdings. Its most notable exit was Prothena Corp, an estimated $4.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 45% a quarter earlier, followed by Technology.

Against the trend, Ghost Tree Capital opened a new position in Allergan plc worth $6.69M.

  • Ghost Tree Capital's largest Q2 2014 buy was Allergan plc: 30,000 shares worth $6.69M.
  • Ghost Tree Capital added most to AtriCure in Q2 2014, an estimated $2.33M increase.
  • Ghost Tree Capital's biggest Q2 2014 reduction was Avadel Pharmaceuticals, cutting an estimated $2.71M.
  • Ghost Tree Capital fully exited Prothena Corp in Q2 2014, selling an estimated $4.21M.
  • Ghost Tree Capital's ten largest holdings make up 46% of its $142M portfolio in Q2 2014.
  • Ghost Tree Capital opened 28 new positions and closed 39 in Q2 2014.
  • Ghost Tree Capital's portfolio value fell 16% quarter-over-quarter to $142M.

Based on Ghost Tree Capital's 13F filing for Q2 2014, filed 14 Aug 2014.